



DURECT to Participate in Upcoming Healthcare Conferences

CUPERTINO, Calif., Aug. 27, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences.

- James E. Brown, President and CEO, will present at the Rodman & Renshaw Investment Conference on Thursday, September 10 at 10:00 a.m. Eastern time. The conference is being held at the St. Regis Hotel in New York City. A live audio webcast of the presentation will be available by accessing <http://wsw.com/webcast/rrshq25/drrx>. Management will also be available for one-on-one meetings at this conference on Wednesday, September 9; interested institutional investors should request a one-on-one meeting through the conference coordinators.
- James E. Brown, President and CEO, will also present at the NewsMakers in the Biotech Industry Conference on Thursday, September 10 at 3:30 p.m. Eastern Time. The conference is being held at the Millennium Broadway Hotel in New York City. A live audio webcast of the presentation will be available by accessing <http://wsw.com/webcast/biocentury/drrx>.
- Matt Hogan, Chief Financial Officer, will also present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 29 at 11:30 am Eastern Time. The conference is being held at the Sofitel Hotel in New York City. A live audio webcast of the presentation will be available by accessing <http://wsw.com/webcast/ladenburg/drrx>. Management will also be available for one-on-one meetings at this conference; interested institutional investors should request a one-on-one meeting through the conference coordinators.

A live audio webcast of these presentations will also be available by accessing DURECT's homepage at www.direct.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a biopharmaceutical company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, CNS disorders, acute organ injury and metabolic diseases. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. Late stage development programs of this nature include POSIDUR™ and REMOXY®. DURECT's Epigenomic Regulator Program includes the lead molecule DUR-928 in Phase 1 clinical testing. DUR-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. For more information, please visit www.direct.com.

NOTE: POSIDUR™ is a trademark of DURECT Corporation. Other referenced trademarks belong to their respective owners. POSIDUR, REMOXY and DUR-928 are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/direct-to-participate-in-upcoming-healthcare-conferences-300133975.html>

SOURCE DURECT Corporation

Matthew J. Hogan, Chief Financial Officer, DURECT, 408-777-4936